Clinical Trials Logo
  1. Home
  2. Anti-Infective Agents
  3. NCT04365101

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 — CYNKCOVID  

Pneumonia Clinical Trial

Official title:
A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19

Clinical Trial Summary

This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Analgesics
  • Anti-infective Agents
  • Antimetabolites, Antineoplastic
  • Antiviral Agents
  • ARDS
  • Communicable Diseases
  • Coronaviridae Infections
  • Coronavirus
  • Coronavirus Infection
  • Coronavirus Infections
  • COVID-19
  • Immune System Diseases
  • Immunologic Disease
  • Immunologic Factors
  • Infections
  • Lung Diseases
  • Nidovirales Infections
  • Physiological Effects of Drugs
  • Pneumonia
  • Pneumonia, Viral
  • Respiratory Tract Disease
  • Respiratory Tract Diseases
  • Respiratory Tract Infections
  • RNA Virus Infections
  • Severe Acute Respiratory Syndrome
  • Severe Acute Respiratory Syndrome Coronavirus 2
  • Virus Disease
  • Virus Diseases
Clinical Trial Details
NCT number NCT04365101
Study type Interventional
Source Celularity Incorporated
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date May 13, 2020
Completion date June 30, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Completed NCT05815264 - Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above Phase 1
Recruiting NCT04589936 - Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care N/A
Completed NCT02905383 - The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital N/A
Terminated NCT03944551 - Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa N/A
Completed NCT06210737 - A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years Phase 4
Terminated NCT04660084 - Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT05702788 - Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) Phase 2
Not yet recruiting NCT04171674 - Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation. N/A
Active, not recruiting NCT03140163 - Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR] N/A
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Completed NCT02638649 - Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
Recruiting NCT02515565 - Physiotherapy in Patients Hospitalized Due to Pneumonia. N/A
Completed NCT02105298 - Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study) N/A
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01416519 - Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation N/A
Completed NCT01399723 - Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia Phase 3
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Terminated NCT02358642 - Drug to Prevent Pneumonia in the Tube Fed Phase 4